FDA Draft Guidance on Genome Editing Could Accelerate CRISPR Therapeutics Rare Disease Pipeline
The FDA has issued draft guidance that may speed approval pathways for rare disease therapies using genome editing technologies, potentially benefiting CRISPR Therapeutics' pipeline of six clinical-stage candidates.
The FDA has issued draft guidance that could speed up approval pathways for rare disease therapies using genome editing technologies. This framework is directly relevant to CRISPR Therapeutics, which focuses on CRISPR/Cas9 based treatments. The guidance, once finalized, may influence how quickly rare disease candidates progress through regulatory review.
For CRISPR Therapeutics, this regulatory move comes at a time when the stock trades around $55.2, with a 24.3% return over the past year and a 15.7% return over the past 3 years. The longer term picture is more mixed, with a 53.6% decline over the past 5 years. At $55.20 versus a $84.78 analyst target, CRISPR Therapeutics trades about 35% below consensus.
In June 2023, CRISPR Therapeutics and Vertex Pharmaceuticals submitted Biologics License Applications to the U.S. Food and Drug Administration for a CRISPR-based therapy targeting sickle cell disease, highlighting ongoing clinical progress. Casgevy, the first CRISPR-based gene therapy approved by the Food and Drug Administration, was developed by CRISPR Therapeutics. Vertex reported higher 2025 sales for Casgevy, a gene-editing therapy for two genetic blood disorders: sickle cell disease and beta thalassemia, and has predicted further sales growth for Casgevy this year.
CRISPR Therapeutics has already shown it has the science to develop groundbreaking gene-editing therapies, and it has five other candidates in clinical trials, all of which have larger potential patient pools than Casgevy. One of the most promising is its cardiovascular disease therapy candidate CTX310, a single-treatment gene therapy that has been shown to reduce triglycerides and LDL cholesterol by more than 80%. Another gene therapy, currently dubbed CTX320, is being studied as a treatment for atherosclerotic cardiovascular disease.
Anticoagulant SRSD107 is a long-acting gene therapy under development with collaborator Sirius Therapeutics to treat patients with thrombosis. And CTX211 is a gene-editing therapy that could restore type 1 diabetes patients' ability to produce insulin.
If the draft guidance eventually translates into clearer and more efficient review paths, it could influence how investors think about timelines and risk around CRISPR based rare disease programs. For now, the key question is how closely CRISPR Therapeutics' ongoing and planned trials will align with the criteria in the FDA's draft framework.
The company remains unprofitable with limited revenue of about $3.51 million. In 2025, it had only $3.5 million in annual revenue, down 91% year over year. However, that was entirely due to an accounting move that the company took in 2024 regarding its collaboration revenue agreements. It also booked a loss of $6.47 per share in 2025, compared to a loss of $4.34 per share in 2024. However, the company has more than $1.9 billion in cash, and if Casgevy sales pick up as expected, it will be able to spend more to develop its pipeline candidates.
The Global Gene Editing Market Size is expected to be worth around $36.9 billion by 2033 from $7.8 billion in 2023, growing at a CAGR of 16.8% during the forecast period 2024 to 2033. By technology, CRISPR emerged as the leading technology, capturing a 53.5% share. North America accounted for the largest share of the gene editing market in 2023, representing 41.2% of the global market.